INTRODUCTION
Immune system development is regulated by the combined action of cytokines, cell-cell interactions, and a distinct set of transcription factors that modulate and coordinate developmental stage-specific and lineage-specific gene expression. Since expression of a specific set of genes is distinct for each cell lineage and each developmental stage, analysis of transcription factors involved in the regulation of these lineage-specific genes is one approach to understand the molecular mechanisms underlying differentiation. Analysis of regulatory regions of B cell-specific genes has revealed the presence of DNA motifs that are repeatedly found in variations and different combinations in most B cell-specific genes. Most B cell-specific genes contain binding sites for different Ets factors such as Pu.1, Ets-1, ELF-1, NERF (ELF2), ERG and factors such as Oct-2, Ikaros, E2A, rel/NF-κB factors, BSAP, LEF-1, N-myc and EBF (1) .
Cooperativity between these different factors leads to selective stage-and cell-specific expression of a particular gene. B cell-specificity of a transcription factor does not always coincides with its exclusive expression in B cells such as the ubiquitously expressed E2A, but rather depends on formation of B cell-specific protein-protein complexes due to the combination of a particular set of factors expressed in B cells.
The ETS transcription factor family plays a key role in cellular differentiation, proliferation, development, apoptosis and immune responses including the growth, survival, and activation of hematopoietic cells (2) . More than 30 Ets family homologues have been cloned (3) , which function as transcription factors under physiological conditions and transform cells when aberrantly expressed. All Ets factors share a highly conserved 80-90 amino acid long DNA binding domain, the ETS domain (4) (5) (6) . This In an effort to search for novel members of the Ets family which might be relevant for B-cell gene regulation, we have previously identified and characterized cDNA clones encoding three alternative splice products of a novel member of the Ets gene family, new Ets-related factor (NERF/ELF2), NERF-1a, NERF-1b, and NERF-2, which differ in their amino termini (8) . NERF is most closely related to ELF-1 and MEF/ELF4. We have demonstrated that both NERF and the related ELF-1 are involved in regulating a set of genes in B cells and myeloid cells and are highly expressed in B cells and myeloid cells (8, 9) . We also showed that NERF-2 is expressed in endothelial cells and transactivates the regulatory regions of the Tie2 gene (10) . Interestingly, NERFby guest on http://www.jbc.org/ Downloaded from 6 2 expression is also increased in endothelial cells in response to hypoxia and to angiopoietin-1 indicating functions for NERF in the immune system and vasculature (11) . AML1 (also known as RUNX1, CBFα2, and PEBP2α2) is a transcription factor critical for definitive hematopoiesis (12, 13) . The AML1 recognition sequence is required for tissue specific expression of several hematopoietic genes including M-CSF receptor, GM-CSF, IL-3, T cell receptors, immunoglobulin µ heavy chain, defensin NP-3, and myeloperoxidase (14) (15) (16) (17) (18) (19) (20) (21) (22) (28, 29) . AML1 (CBFα2) forms a heterodimer with CBFβ. CBFβ does not bind DNA directly but enhances the binding of AML1 (30) . Multiple α subunit genes, including CBFα1 (AML3), CBFα2 (AML1), and CBFα3 (AML2), as well as alternatively spliced isoforms of the α and β subunits have been detected (31, 32) . All of the CBFα proteins have a DNA-binding domain (the runt domain), which is similar to the Drosophila pair-rule gene, runt (33) . To understand the function and role of AML1 in leukemia it is important to study the molecular mechanism of AML1 mediated regulation of gene expression.
Ets related binding sites are evident in most B cell-specific genes. Hematopoetic genes containing high affinity NERF/ELF-1 binding sites include among others: IgH, Terminal deoxynucleotidyltransferase (TdT) (34, 35) , mb-1, B29 (36) , BSAP (37) , lck (38) , blk (39) , lyn (40, 41) . Blk is a B cell-specific tyrosine kinase which is expressed in by guest on http://www.jbc.org/ Downloaded from 7 preB and mature B, but not in plasma cells; this is similar to the expression of mb-1 and B29 (42) . Blk is associated with the antigen receptor and involved in signal transduction (39) . The blk promoter contains a previously uncharacterized NERF/ELF-1 binding site adjacent to a BSAP and AML1 site. Not much is known about regulation of blk gene expression except that the B cell-specific transcription factor BSAP plays an important role and that the transcription factor NF-κB/p50 interacts with the blk gene during B cell activation (41) . We, furthermore, demonstrated that AML1 binds to the blk promoter and cooperatively transactivates the blk promoter in the presence of BSAP (43) . AML1 has been previously shown to interact with a variety of Ets factors including the related MEF indicating that a possible interaction between AML1 and NERF may play a role in blk gene regulation (44) .
We now report that NERF-2 and ELF-1 directly interact with the runt homology domain of AML1 through a basic region upstream of the Ets domain, and cooperate with AML1 in activating blk promoter transcription. We also demonstrate that the NERF-1a isoform lacks the NERF-2 transactivation domain and represses AML1 mediated transactivation of the blk promoter. 
MATERIALS AND METHODS

Plasmid Construction
Full length and different fragments of NERF-2, NERF-1a, and ELF-1 were cloned into pGEX-5X-3 vector to make GST fusion proteins in BL21 Escherichia coli Strain (Novagen). The expression vectors of full-length AML1, AML1 -208 , and AML1 87-208 are all derived from AML1B and were prepared as reported previously (45) . Lyn and blk promoter constructs were also prepared as reported previously (8) . For expression of NERF-2 in mammalian cells, NERF-2 was cloned into the Not I site of the pCi vector which has a CMV promoter and enhancer. 
Cell Culture and Transfection
CV-1 and Human Embryonic Kidney (HEK) 293T cells were grown in DMEM (BioWhittaker) containing 10% FBS and penicillin/streptomycin. Co-transfections of 3x10 expression vector DNA using 12.5 µl Lipofectamine (Invitrogen) as described previously (45) . The cells were harvested 16 hours after transfection and assayed for luciferase activity as described previously (43) . Transfections for every construct were performed independently in duplicates or triplicates and repeated 3 to 4 times with two different plasmid preparations with similar results.
In Vitro Translation
Protein in vitro translation was performed using the TNT T7-coupled reticulocyte lysate system according to the manufacturer's protocol (Promega 
GST Pull-down Experiments
The GST-pull down experiments were performed as described previously with some modification (46) . The integrity of the bacterially expessed GST fusion proteins was examined by SDS-PAGE, followed by Coomassie blue staining. Approximately equal amounts of the fusion proteins were used for each reaction. Briefly, the GST-fusion proteins were expressed in BL21 E. coli, expression was confirmed and quantified by SDS-PAGE, and GST-fusion proteins were immobilized on glutathione Agarose beads for pull-down assays as described (46) . 
RESULTS
NERF-2 Physically Interacts with AML1
Our previous studies established that the promoter region of the B cell-specific blk gene contains Ets-and AML1-binding sites in close proximity to each other (43) . Since AML1 has been shown to interact and cooperate with other Ets transcription factors including Ets-1 and MEF, we explored the possibility that NERF-2 which activates the blk promoter can cooperate with AML1 in regulating blk gene expression (8) . We first tested whether NERF-2 directly interacts with AML1 using a GST-pull down assays, in which Escherichia coli expressing GST fusion proteins immobilized on glutathioneagarose beads were incubated with in vitro translated 
A Basic Region Upstream of the Ets Domain of NERF-2 Interacts with AML1
To map the region of NERF-2 responsible for interaction with AML1, showed that the N-terminus of NERF-1a interacts with AML1 as well, further supporting that the basic region of NERF is involved in binding to AML1.
NERF-2 binds to AML1 in vivo.
To confirm that NERF-2 can bind to AML1 in vivo, we performed a coimmunoprecipitation experiment. For this purpose, we generated expression vectors for a fusion protein of NERF-2 containing the Flag tag at the N-terminus and for a fusion protein of AML1 containing the MYC tag at the C-terminus. These constructs were either individually transfected or co-transfected into 293T cells. Total cell lysates were immunoprecipitated using anti-Flag conjugated agarose beads followed by Western blot analysis with anti-MYC antibody. Vector alone, NERF-2-5Flag or AML1-3myc itself did not give any signal. AMLl, however, was detected clearly when NERF-2-5Flag and AML1-3myc were co-transfected into the cells (Fig. 3A) . These data most vividly demonstrate that AML1 protein binds to the NERF-2 protein in vivo.
AML1 interacts with selected other members of the ETS family in vivo.
To test if AML1 interacts with other ETS family members in vivo, the AML1-3myc construct was co-transfected with either NERF-2-5Flag, MEF-5Flag, PDEF-5Flag, or ESE1-5Flag into 293T cells (Fig 3B) . The expression of each ETS-5Flag construct was then tested by SDS-PAGE and Western Blot using the Flag antibody.
Immunoprecipitation with the Flag antibody followed by Western blot analysis with the AML1 antibody revealed that AML1 binds to NERF-2 and MEF as expected. However, no binding of AML1 to PDEF or ESE1 was detected demonstrating that AML1 interacts with a selected subset of the Ets family.
NERF-2 cooperates with AML1 in transactivation of the blk promoter, but NERF-1A
represses AML1 mediated transactivation.
To evaluate whether AML1 interaction with NERF leads to cooperativity in the context of the blk promoter, we performed co-transfection experiments. NERF-2 and AML1 together with its non-DNA-binding heterodimer partner CBFβ, either alone or in combination, were co-transfected along with the blk promoter-luciferase construct into CV-1 cells and luciferase assays were performed 16 hours later. NERF-2 activated the blk promoter 3.6-fold and AML1c (which is longest form of AML1 splice variants, with 480aa) 12-fold. However, the combination of NERF-2 with AML1c led to a synergistic increase in blk promoter activity of 42-fold which is significantly more than would be expected due to an additive effect (Fig 4A) . This experiment clearly demonstrates that NERF-2 cooperatively enhances AML1 mediated transactivation of the blk promoter. In To evaluate whether these mutants were able to cooperate with AML1 in transactivation of the blk promoter, CV-1 cells were transiently co-transfected with wild type or mutant NERF-2 and AML1 together with CBFβ, either alone or in combination (Fig 4D) .
Deletion of amino acids 108-180 resulted in complete loss of cooperativity with AML1
by guest on http://www.jbc.org/ Downloaded from when compared to the activity induced by wild type NERF-2 ( Fig 4D) . Transactivation of the blk promoter by these mutants alone was also slightly reduced and may be the result of reduced transactivation capacity due to either lack of interaction with endogenous AML1 or an effect on the basal transactivation capacity of NERF-2, even though neither the transactivation domain (see below) nor the DNA binding domain were changed.
These data clearly demonstrate that disruption of NERF-2 interaction with AML1 results in the loss of transcriptional cooperativity of NERF-2 with AML1 and that the AML1 interaction domain is critical for cooperativity.
To determine whether the transactivation domain of AML1 is essential for cooperativity with NERF-2 AML1 mutants truncated at the carboxy terminus were transfected in the absence or presence of NERF-2 into CV-1 cells (Fig. 4E ). While termination of AML1 at amino acid 381 and 351 did not affect cooperativity with NERF-2 or transactivation by AML1 alone, termination at amino acid 289 drastically reduced cooperativity and correlated with the loss of transactivation capability of AML1 itself.
These results reveal that the C-terminal transactivation domain of AML1 is necessary for synergy with NERF-2.
NERF-2, but not NERF-1A contains a transactivation domain encoded by the aminoterminal 100 amino acids.
Although NERF-2 and NERF-1A were able to interact with AML1, only NERF-2 acts as a transcriptional activator and cooperates with AML1. This result suggests that the (Fig. 5A) . NERF-1A which lacks the amino-terminus of NERF-2 and instead has a distinct amino-terminus did not transactivate the lyn promoter Ets site either and actually slightly decreased promoter activity compared to the parental pCI expression vector. These data provide strong evidence that the main NERF-2 transactivation domain is located at the amino-terminus that is absent from NERF-1A.
These data also demonstrate that the transactivation domain is distinct from the AML1 interaction domain.
To confirm that the N-terminal deletion NERF-2 does not affect protein expression, protein stability or binding to the lyn promoter, we performed EMSAs using Fig. 7A and B) . We hypothesized that evolutionary conservation of these acidic domains may indicate an important function for these domains. Deletions A, B, and D reduced transactivation to about 50% compared to wild type NERF-2, and a combined deletion of domains A and B (Mut A+B) further reduced transactivation, but not to the level observed by the full amino-terminal deletion (Fig. 5B) . Deletion of domain C (Mut C), in contrast, did not affect transactivation capacity (Fig. 5B ). These results demonstrate that the amino-terminal conserved domains A and B, but not C are integral components of the NERF-2 transactivation domain which is either absent or truncated in NERF-1A and NERF-1B. To confirm that the differences in transactivation capability of NERF-2 deletion mutants are not due to reduced levels of expression in transfected cells or reduced DNA binding, we performed EMSAs using 21 aliquots of the cell extracts from transfected CV-1 cells (Fig. 6 ). All NERF-2 deletion mutants formed complexes with expected mobility and similar intensity suggesting that decreases in transactivation are not due to a lack of or reduced expression, or a lack of DNA binding. The fact that deletion of NERF-2 domains A and B together drastically impairs, but does not abolish transactivation activity completely suggests that there is an additional region in the N-terminus (aa 1-103), which contributes to the transactivation of NERF-2 (Fig. 5B ).
To further confirm that the amino-terminus of NERF-2, but not NERF-1A
exhibits transactivation activity, we fused different domains of NERF-2 and NERF-1 to the Gal4 DNA binding domain and tested their transactivation activities on the luciferase reporter containing 3 binding sites for GAL4 fused to a minimal promoter. We cotransfected each of these constructs into COS cells along with the Gal4luc reporter (pGSE1bluc or pSGluc1b). As predicted by our deletion mutants, the amino-terminus of NERF-2 strongly transactivated the GAL4 luciferase reporter by up to 900 fold compared to the GAL4 DNA binding domain alone (Fig. 8 ). This activation was equally strong as or AML1/ETO due to these protein-protein interactions. We have previously demonstrated that AML1 directly interacts with the B cell specific transcription factor BSAP/PAX-5 and that this interaction leads to synergistic enhancement of transactivation of the B cell specific blk gene promoter (43) . We also previously showed that the blk promoter is regulated by the Ets factors NERF-2 and ELF-1 that are expressed in B cells (8) .
In this study, we examined the physical interaction of NERF-2 and NERF-1 with The AML1 interaction domain of NERF-2 was mapped to a basic domain upstream of the Ets domain which differs from Ets-1 binding to AML1. AML1 binds to the Ets domain of Ets-1 and autoinhibitory domains (NRBD and exon VII domain) (47) .
We also show, as has previously been demonstrated in vitro, that MEF, a NERF-2 homologous protein, binds to AML1 in vivo. MEF has also been reported to interact with AML1 through a region amino-terminal to the Ets domain, although this region was not further defined (48) . Therefore, it is likely that the basic domain D which is conserved among E74 Ets family members is the region in which NERF-2, MEF and Elf-1 interact with AML1. Thus, this AML1 interacting domain appears to represent a novel protein- vectors in an EMSA using oligonucleotides encompassing the lyn promoter Ets site. This result shows that the NERF-2 mutants used for the experiments in Figure 5A and 5B does not affect or has little effect on the DNA binding activity to the blk or lyn promoter. by guest on 
